MAP-AI
Research type
Research Study
Full title
Medication adherence in pregnancy study- Aspirin-Include (MAP-AI) Evaluating barriers to low dose aspirin adherence in underserved women and healthcare staff.
IRAS ID
325986
Contact name
Anna Davies
Contact email
Sponsor organisation
North Bristol NHS Trust
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Current NICE guidelines recommend the use of low dose aspirin(LDA; 75-150mg) daily for pregnant women with risk of placental problems. Placental problems can cause high blood pressure that develops in pregnancy (pre-eclampsia), which can cause death for the mother and baby, as well as growth problems and early delivery for the baby. Growth problems and early delivery can have a long term impact on a baby's development and wellbeing. All women are risk assessed for placental problems at the start of pregnancy, and those with risk factors are recommended LDA.
Trials show LDA is safe and effective for preventing these negative outcomes for mother and baby. However, our research in Bristol, and research from other countries shows that many women take less LDA than recommended or not at all (between 40-60% are non-adherent). In our previous research interviews we found that many women do not understand why they've been recommended it and have been unable to get clear information from health care practitioners. Some had difficulties remembering to take it. The women in this study were typically White, and from higher education and higher income (SES) backgrounds. Findings from other studies show that women who are Black, Asian, younger mothers, smokers and from lower SES families have poorer birth outcomes and are less likely to take LDA.
In this research study we aim to explore the experiences of women from these underserved groups around being recommended LDA, to identify ways in which we can increase adherence to it. We also want to understand the views of Midwives, doctors, GPs and pharmacists to understand how best to promote taking LDA. To do this we will interview women from these groups, and healthcare staff, to explore their experiences and get their ideas about how to intervene to increase adherence.REC name
Wales REC 5
REC reference
23/WA/0121
Date of REC Opinion
4 May 2023
REC opinion
Further Information Favourable Opinion